Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Lr[2lEPTB;MD6wNFY3QSEQvF2= NHXLPVRUSU6JRWK=
MV-4-11 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEG1PFYh|ryP NV\peWZPW0GQR1XS
NKM-1 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TvUGlEPTB;MD6wNVY6QSEQvF2= MUXTRW5ITVJ?
ML-2 MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMEG5PFMh|ryP MULTRW5ITVJ?
BV-173 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjre4xKSzVyPUCuNFI{OTRizszN MmnhV2FPT0WU
RS4-11 NXrWTI1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvrdWlyUUN3ME2wMlAzPTh5IN88US=> MWjTRW5ITVJ?
HL-60 NUG2N|F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL3eYtlUUN3ME2wMlAzQTB6IN88US=> NUHEfFAxW0GQR1XS
KY821 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEK5O|Uh|ryP NHrvU|RUSU6JRWK=
ECC10 M{W5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTNTWM2OD1yLkCzO|kzKM7:TR?= NXT1b4ZlW0GQR1XS
NCI-H720 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHaO284UUN3ME2wMlA1ODFzIN88US=> NGDIU3BUSU6JRWK=
QIMR-WIL MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2wXGE4UUN3ME2wMlA1Ojh5IN88US=> Mn;tV2FPT0WU
KG-1 NVzBVHB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\nUYQ5UUN3ME2wMlA1PDh4IN88US=> MW\TRW5ITVJ?
TGW MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfNTWM2OD1yLkC0OlM{KM7:TR?= NIrMPYpUSU6JRWK=
ATN-1 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMES3N|Mh|ryP NF3vR3pUSU6JRWK=
RH-18 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[zTWM2OD1yLkC2NFQ5KM7:TR?= NUTKeYoxW0GQR1XS
EW-18 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m5OGlEPTB;MD6wOlg1OSEQvF2= M2rj[HNCVkeHUh?=
NB17 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEexNlQh|ryP NX3r[mlvW0GQR1XS
SK-NEP-1 NInYRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLLNYJ1UUN3ME2wMlA4OjF|IN88US=> M3z1XHNCVkeHUh?=
P12-ICHIKAWA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEe3O|gh|ryP NGnsVZdUSU6JRWK=
KARPAS-45 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjhR4xnUUN3ME2wMlA4QDF3IN88US=> MU\TRW5ITVJ?
EW-3 NWW0WlQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz0cXBbUUN3ME2wMlA5ODV|IN88US=> M3LnU3NCVkeHUh?=
NB13 M4XveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEiyNFMh|ryP MXLTRW5ITVJ?
NCI-H209 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEi3NFQh|ryP MlHhV2FPT0WU
NCI-H1092 NGezTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2qzNWlEPTB;MD6xNFI4PSEQvF2= NFXrR2lUSU6JRWK=
NH-12 M2jJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LX[mlEPTB;MD6xNFc1PCEQvF2= MULTRW5ITVJ?
697 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jTeGlEPTB;MD6xNFg{QSEQvF2= MULTRW5ITVJ?
KE-37 NHvsdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HBSmlEPTB;MD6xNVM4KM7:TR?= MXjTRW5ITVJ?
MOLT-4 NUTielJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnvTWM2OD1yLkG1NVY6KM7:TR?= NXfKSYFpW0GQR1XS
CHP-134 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[4eGlEPTB;MD6xOlMxPiEQvF2= M4L6W3NCVkeHUh?=
D-283MED NIHMNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTVVGxSUUN3ME2wMlE4Pjh4IN88US=> NXTkcZgyW0GQR1XS
LU-135 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMUi1OVIh|ryP MnzGV2FPT0WU
LU-134-A MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMUi2O|Eh|ryP MnrTV2FPT0WU
EM-2 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfrTZRKSzVyPUCuNVk6OThizszN MlO2V2FPT0WU
LU-139 NI[zVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf0ZnRKSzVyPUCuNlA1QThizszN NYe1TldOW0GQR1XS
ALL-PO MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG2d2RKSzVyPUCuNlE6QDhizszN NUT1V253W0GQR1XS
NB12 NYPxSFZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMkOxNVUh|ryP M3HKTnNCVkeHUh?=
KP-N-YN NVX2RXRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnZdJFtUUN3ME2wMlI{PTd|IN88US=> NVLVWHRIW0GQR1XS
BEN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2xOHNKUUN3ME2wMlI{QTZ6IN88US=> MVrTRW5ITVJ?
HCC1569 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L1b2lEPTB;MD6yOVExPiEQvF2= MXnTRW5ITVJ?
HuO9 NIHRNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;lVmlEPTB;MD6yOlcyPSEQvF2= NXfKWI9vW0GQR1XS
WM-115 Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrGTWM2OD1yLkK3O|M5KM7:TR?= MkDYV2FPT0WU
CCRF-CEM NFPi[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHJTIFQUUN3ME2wMlM{PTJ7IN88US=> MUjTRW5ITVJ?
IST-SL1 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:1R3VKSzVyPUCuN|U{PDNizszN MmHJV2FPT0WU
BE-13 NYjFR2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLoTWM2OD1yLkO2OFU6KM7:TR?= NFfSeYRUSU6JRWK=
COR-L88 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfJdmFVUUN3ME2wMlM3PTRizszN Mn;0V2FPT0WU
DOHH-2 M{S3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvk[HBtUUN3ME2wMlQyODJ|IN88US=> MmrPV2FPT0WU
A704 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO2WGZuUUN3ME2wMlQzPjdizszN NWjJXph4W0GQR1XS
KNS-81-FD NGD5O4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn4cot6UUN3ME2wMlQ1ODF5IN88US=> NHrvb49USU6JRWK=
RPMI-8226 NIHTc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmezTWM2OD1yLkS1OlUzKM7:TR?= M2HUUHNCVkeHUh?=
TGBC24TKB MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzhXoZLUUN3ME2wMlQ2Pzd6IN88US=> MYnTRW5ITVJ?
NCI-H1304 M4SzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwNE[xOVch|ryP NEjqRlZUSU6JRWK=
MOLT-13 NIHPbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W5WmlEPTB;MD60OlYyOyEQvF2= NHjqcFJUSU6JRWK=
EW-22 NYP1VHN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNE[2O|Eh|ryP NWrk[21jW0GQR1XS
MS-1 NGfaRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD1yLkS2PVM{KM7:TR?= MlXQV2FPT0WU
RMG-I MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHIOm9KSzVyPUCuOFk1PjRizszN NUKxbmQ1W0GQR1XS
NTERA-S-cl-D1 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PaW2lEPTB;MD61NFAyQSEQvF2= NVK0O3JoW0GQR1XS
NCI-H1048 NUf5OIZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwNUC5OVMh|ryP M33YTHNCVkeHUh?=
SW1417 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNUW0N|gh|ryP M2\H[HNCVkeHUh?=
DB NYn6ZpB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNUewPEDPxE1? MWDTRW5ITVJ?
MEG-01 NXPSO2g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHuTWM2OD1yLkW4N|Ih|ryP NHTjWHVUSU6JRWK=
EW-13 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnPfZB7UUN3ME2wMlU5OzRzIN88US=> MmTjV2FPT0WU
LAMA-84 NH\qS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq1TWM2OD1yLkW5NlA4KM7:TR?= NWC5bWI6W0GQR1XS
J-RT3-T3-5 M1\vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwNkC4NFgh|ryP NYXrb5d1W0GQR1XS
MOLT-16 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNkWyOlQh|ryP MmHDV2FPT0WU
DU-4475 NH3GbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKzR3RlUUN3ME2wMlY2PDJ5IN88US=> NV7uXY1mW0GQR1XS
HAL-01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\3[oxKSzVyPUCuO|I2PDlizszN Mnu0V2FPT0WU
RD M2XyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwN{W4PVkh|ryP MXrTRW5ITVJ?
OAW-28 NXLNOmJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXVTWM2OD1yLke4N|ch|ryP NUPBd4FGW0GQR1XS
HCC38 M4fTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjyZ|V5UUN3ME2wMlgxOTlizszN Mki4V2FPT0WU
NMC-G1 M4PHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjjTWM2OD1yLkixNVIyKM7:TR?= NVrtZZNrW0GQR1XS
EW-16 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj6N45PUUN3ME2wMlgyOzJ6IN88US=> NGnTfnpUSU6JRWK=
DU-145 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXZUIk1UUN3ME2wMlg6QTJ|IN88US=> MnzFV2FPT0WU
HPAF-II MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnvW3Y1UUN3ME2wMlkzPjJ6IN88US=> MWHTRW5ITVJ?
A427 NEfi[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOUOwNlIh|ryP MnHPV2FPT0WU
PA-1 NHru[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrxempKSzVyPUCuPVU3PDJizszN NILlcFVUSU6JRWK=
OAW-42 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwOU[xOFYh|ryP MUfTRW5ITVJ?
L-428 NVj5V3JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGxXFZKSzVyPUGuNFEzPSEQvF2= NUHHO3dsW0GQR1XS
COLO-824 NWrhSpdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfJcpRpUUN3ME2xMlAyPzB6IN88US=> NHXCRZNUSU6JRWK=
P30-OHK M33jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwMES2PFgh|ryP NHXLZlBUSU6JRWK=
NCI-H2170 M2TC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELPVmRKSzVyPUGuNFYzOyEQvF2= MV7TRW5ITVJ?
HCC2998 M4HJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTrTWM2OD1zLkC3NVM2KM7:TR?= M1;idnNCVkeHUh?=
NB14 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjmN|Y3UUN3ME2xMlE{PzR6IN88US=> MmfEV2FPT0WU
TGBC1TKB MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfkTWM2OD1zLkG0NVUzKM7:TR?= MWrTRW5ITVJ?
KP-N-YS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm4fVQzUUN3ME2xMlE3OjN4IN88US=> M{fDZ3NCVkeHUh?=
CAL-120 NVvSSVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDJTGxNUUN3ME2xMlE3PDJ7IN88US=> MlfzV2FPT0WU
SBC-1 MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMUmwOVMh|ryP MYfTRW5ITVJ?
C32 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlexTWM2OD1zLkG5NFg5KM7:TR?= NEjjbVJUSU6JRWK=
HCC2157 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjmVlRMUUN3ME2xMlE6PDl2IN88US=> M1vKNHNCVkeHUh?=
COLO-792 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi3WGVKSzVyPUGuNlAxPzFizszN MlTsV2FPT0WU
ES7 NFHH[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPHS45KSzVyPUGuNlc6PTFizszN NVfQVJY4W0GQR1XS
HEL NHL4[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzUW5pxUUN3ME2xMlMyODJ7IN88US=> Mn71V2FPT0WU
ES4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXCN|FiUUN3ME2xMlM1QTl6IN88US=> M3G5THNCVkeHUh?=
NCI-SNU-1 M4Tqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX4V4FKSzVyPUGuN|Y2PTVizszN NHfHfIlUSU6JRWK=
MDA-MB-415 NVjZU2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fIb2lEPTB;MT6zPFg2KM7:TR?= MnexV2FPT0WU
NCI-H2342 NE\FUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\1VFhmUUN3ME2xMlQxOjZ7IN88US=> MomxV2FPT0WU
NB69 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fqNGlEPTB;MT60OlI4OSEQvF2= M2\adHNCVkeHUh?=
D-247MG NHPB[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XNOGlEPTB;MT61NVEzOiEQvF2= MUfTRW5ITVJ?
SCC-4 MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zWOmlEPTB;MT61PVg5PyEQvF2= M3nyRXNCVkeHUh?=
HuH-7 M4HSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPXTWM2OD1zLk[3Nlk{KM7:TR?= MX;TRW5ITVJ?
A388 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7CRXVKSzVyPUGuOlg4OjRizszN Mmn5V2FPT0WU
Calu-3 NVHXc5JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPSSFBKSzVyPUGuO|A3QTdizszN MUDTRW5ITVJ?
NCI-H1648 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXlSFdKSzVyPUGuO|E1OThizszN M37Kd3NCVkeHUh?=
NCI-H2052 NInucmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zhW2lEPTB;MT63NlIxOSEQvF2= MWnTRW5ITVJ?
Ramos-2G6-4C10 M3\YR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjtTWM2OD1zLkezOlU3KM7:TR?= M{PqfHNCVkeHUh?=
DEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwN{S2PVIh|ryP M{LuNXNCVkeHUh?=
SNU-423 NITFcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXpTWM2OD1zLke4NVU4KM7:TR?= NFPFS|VUSU6JRWK=
COR-L23 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HZR2lEPTB;MT63PVg4PCEQvF2= MX3TRW5ITVJ?
OMC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XGNWlEPTB;MT64OlAyPiEQvF2= Mlq2V2FPT0WU
EW-11 NVTKNGZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX0TWM2OD1zLkm1OlU4KM7:TR?= MXfTRW5ITVJ?
HSC-3 NFi1ZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fQZ2lEPTB;MT65OlM3PSEQvF2= M2fwVXNCVkeHUh?=
MLMA NF65eotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\KcXhKSzVyPUGuPVY3PzdizszN NGHjT2hUSU6JRWK=
RCM-1 NHvsdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPYd5ZKSzVyPUKuNFA{QTlizszN MVnTRW5ITVJ?
MFE-280 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXziV3ZqUUN3ME2yMlAzQDR6IN88US=> MXfTRW5ITVJ?
ES8 NH\1d|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHztSpJKSzVyPUKuNlU1PzFizszN NULJPYVvW0GQR1XS
TE-11 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILQOoZKSzVyPUKuNlk1PzNizszN NWq2RlFKW0GQR1XS
HuO-3N1 NU\qWJk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwNEi3PEDPxE1? MY\TRW5ITVJ?
MHH-NB-11 NXHCRXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwNUGxOVgh|ryP MljkV2FPT0WU
TGBC11TKB M3PVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nObmlEPTB;Mj61O|Y5OSEQvF2= MmX4V2FPT0WU
HOP-92 M1\tO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPMdFNKSzVyPUKuOVg4PDNizszN NX\EXIwxW0GQR1XS
IGR-1 M3Hy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwNkKwN|Uh|ryP MXLTRW5ITVJ?
GOTO MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33icGlEPTB;Mj62OVM4PyEQvF2= MVjTRW5ITVJ?
NCI-H1650 NYS5fWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGraPHFKSzVyPUKuO|IzOTVizszN NHXheY9USU6JRWK=
NCI-H1581 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTGT|BKSzVyPUKuO|k3QDFizszN NF3mVnlUSU6JRWK=
NCI-H2405 M{LITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\uOIZuUUN3ME2yMlgzPzh{IN88US=> MmLhV2FPT0WU
U-118-MG NEXv[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjWVZdKSzVyPUKuPVY1QTFizszN NV7QNWtsW0GQR1XS
DoTc2-4510 M4q5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Lhc2lEPTB;Mz6wNVQyPyEQvF2= MUXTRW5ITVJ?
NCI-H596 NWXyWpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\qTWM2OD1|LkC0PVk4KM7:TR?= NFrjOYVUSU6JRWK=
MPP-89 M2rvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PjeGlEPTB;Mz6wOVY3PiEQvF2= NV;CXGZYW0GQR1XS
GCIY NWH2dZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwMkC0PVEh|ryP NWPadJdlW0GQR1XS
SW626 M{nT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvLTWM2OD1|LkK0OVQ{KM7:TR?= NGfJNFFUSU6JRWK=
OCI-AML2 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M172[mlEPTB;Mz6zNVI4OiEQvF2= NFXPc3lUSU6JRWK=
NBsusSR M3H4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fs[2lEPTB;Mz6zOFk{QCEQvF2= MX7TRW5ITVJ?
AN3-CA MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[x[GlEPTB;Mz60OFI{QCEQvF2= MkHGV2FPT0WU
EFM-19 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Lz[GlEPTB;Mz60PFM{QSEQvF2= NVTYRnk3W0GQR1XS
RVH-421 NYXpVlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37zOmlEPTB;Mz61Olg4PyEQvF2= MX;TRW5ITVJ?
5637 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnENpFXUUN3ME2zMlYyOTB|IN88US=> M13uZnNCVkeHUh?=
PANC-08-13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf0eosyUUN3ME2zMlY{PDd{IN88US=> MmfJV2FPT0WU
H9 NFHBVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwNkexOFQh|ryP M3rNcXNCVkeHUh?=
KARPAS-299 NFu4UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNwNkezOlEh|ryP MkfaV2FPT0WU
TE-5 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2roTGlEPTB;Mz63NFcxQSEQvF2= MVTTRW5ITVJ?
NOS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHyTWM2OD1|Lke5PFM1KM7:TR?= NEHCV4lUSU6JRWK=
HH MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNwOEO4Olgh|ryP M3jsXnNCVkeHUh?=
769-P M1yxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHlTWM2OD1|Lki5OVEh|ryP NGCycpNUSU6JRWK=
CHP-212 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof3TWM2OD1|LkmyOVQ6KM7:TR?= M3PLd3NCVkeHUh?=
NCI-H82 M3jT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELSbpdKSzVyPUOuPVU6OzZizszN M3\QVnNCVkeHUh?=
Mo-T NHmxZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rSdWlEPTB;ND6wOFMyOiEQvF2= MnnUV2FPT0WU
BB65-RCC MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e5U2lEPTB;ND6wOFM6QSEQvF2= NIDVTmlUSU6JRWK=
SW1990 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRwMEW5NFgh|ryP NG\oTGxUSU6JRWK=
LK-2 NV3RNmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwMUGyPVMh|ryP MlTPV2FPT0WU
ES5 NYPSSHY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLmO4ZKSzVyPUSuNVM6QDVizszN NFjyZ5JUSU6JRWK=
JVM-3 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTRwMUiyNlIh|ryP MW\TRW5ITVJ?
RPMI-7951 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jPZ2lEPTB;ND6yNlQyOyEQvF2= NWi1dHViW0GQR1XS
Calu-6 NXHDUWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\JTWM2OD12LkK3PFgyKM7:TR?= NIW5WG1USU6JRWK=
LC-2-ad NYXlXlR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XNPWlEPTB;ND6yPVU3QCEQvF2= NFS1NINUSU6JRWK=
SW954 M4DHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwMkm2OkDPxE1? NWP4[ZY2W0GQR1XS
H-EMC-SS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3PdG1KSzVyPUSuN|E5OzFizszN MlPLV2FPT0WU
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRwM{W0OFEh|ryP NH23[VVUSU6JRWK=
no-11 NXXQUGw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRwM{W1OVQh|ryP MVrTRW5ITVJ?
LAN-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTiR2ZKSzVyPUSuOFUyQDlizszN MXTTRW5ITVJ?
FTC-133 M{nUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO3V5N3UUN3ME20MlU{QTVizszN MV3TRW5ITVJ?
8505C NHLOZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TMVWlEPTB;ND61OFI{KM7:TR?= M1vhbXNCVkeHUh?=
SW620 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRwNUewOVch|ryP M2PvUHNCVkeHUh?=
BCPAP M3H4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjVbmt1UUN3ME20MlY{PDhzIN88US=> MYDTRW5ITVJ?
SK-LU-1 NVP2VmRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwNk[wPFkh|ryP NHnSVppUSU6JRWK=
NCI-H1623 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzlTJBnUUN3ME20MlcxOjJ6IN88US=> MXPTRW5ITVJ?
C2BBe1 M3H6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fLRmlEPTB;ND63OFAxQCEQvF2= M4\kVnNCVkeHUh?=
GP5d NEjPZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PvV2lEPTB;ND63PFM5QCEQvF2= MknTV2FPT0WU
NB6 NW\EVWJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHqNVVKSzVyPUSuPFYzODRizszN MnLMV2FPT0WU
MDA-MB-157 M1\P[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRwOEi3OkDPxE1? M1LJOHNCVkeHUh?=
UMC-11 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ETWM2OD12Lki4PVY1KM7:TR?= NVz2[|JEW0GQR1XS
HCC1419 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTRwOUCwOlMh|ryP NGDyXmlUSU6JRWK=
NCI-H2029 NIfWdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTRwOUSxPFUh|ryP NHTHTIFUSU6JRWK=
LXF-289 NW\0UlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTVwMEO3NVkh|ryP MUPTRW5ITVJ?
KINGS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHCTWM2OD13LkC3O|Q1KM7:TR?= MlHaV2FPT0WU
HD-MY-Z MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;3NnhQUUN3ME21MlI{QTZ7IN88US=> NYi4cnBVW0GQR1XS
ESS-1 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\CTWM2OD13LkK1OVk4KM7:TR?= MlXGV2FPT0WU
GI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX3TWM2OD13LkK3PVI3KM7:TR?= MnH0V2FPT0WU
RPMI-2650 M2f1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvkOXEzUUN3ME21MlM3OTZizszN MkXGV2FPT0WU
IA-LM Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljhTWM2OD13LkO5PFcyKM7:TR?= MVzTRW5ITVJ?
KP-4 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m5UGlEPTB;NT60OlM{PCEQvF2= NF:yd|VUSU6JRWK=
G-402 M3SxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly0TWM2OD13LkWxPFY2KM7:TR?= M3vPeXNCVkeHUh?=
OS-RC-2 M4XVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjsUmc6UUN3ME21MlUzPjB2IN88US=> MVHTRW5ITVJ?
NCI-H1155 NH33TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7sXG5{UUN3ME21MlU1QTV3IN88US=> MXTTRW5ITVJ?
OE19 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL1XmRKSzVyPUWuOlg3OjRizszN NUDiOZcxW0GQR1XS
U-2-OS Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILHUWJKSzVyPUWuPFkxOTNizszN MYnTRW5ITVJ?
SCC-15 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjsfJltUUN3ME21Mlk{PjZ{IN88US=> MnLWV2FPT0WU
NCI-H630 NYTzbFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnmb5p6UUN3ME21Mlk6PDB2IN88US=> MYrTRW5ITVJ?
PFSK-1 NVn5fVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrYS5BbUUN3ME22MlA2OjV7IN88US=> MlnmV2FPT0WU
NCI-H1770 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTZwMkC4O|Qh|ryP MYPTRW5ITVJ?
SK-MEL-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZwNEK5NVUh|ryP NELGTFBUSU6JRWK=
LB1047-RCC Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofrTWM2OD14LkS3OlI2KM7:TR?= MoLoV2FPT0WU
NCI-H446 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZwNkK5NlUh|ryP M3rz[XNCVkeHUh?=
SW780 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nUW2lEPTB;Nj63NFE5PSEQvF2= NGfJW|lUSU6JRWK=
NEC8 NX\STXpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHTb5QzUUN3ME22Mlc3PjNizszN Mom1V2FPT0WU
NOMO-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHPbVVKSzVyPU[uO|gyOTFizszN NV7Y[HpPW0GQR1XS
COLO-668 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHMRYhRUUN3ME22Mlg1Ozh5IN88US=> M3PNdHNCVkeHUh?=
MC116 M3HIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrEW4RKSzVyPU[uPVM5QTdizszN MkTZV2FPT0WU
HCC1937 M{nzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZwOUmyOVEh|ryP NEL0VYtUSU6JRWK=
NCI-N87 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;mUGlEPTB;Nz6xPVI6OyEQvF2= MYnTRW5ITVJ?
COLO-320-HSR NF7K[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLmclc4UUN3ME23MlIzPzN6IN88US=> NUO1UJFSW0GQR1XS
HCC1806 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fXcWlEPTB;Nz6yOlA1PCEQvF2= NH62eVlUSU6JRWK=
OVCAR-3 MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTdwM{OwN|gh|ryP M1LuW3NCVkeHUh?=
NUGC-3 NGTTcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\pVlRKSzVyPUeuN|k3QTRizszN NGXFbphUSU6JRWK=
SW1783 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHP[HFjUUN3ME23MlQ{OTd3IN88US=> Mn7oV2FPT0WU
GCT NUPnZo5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdwNU[5NFYh|ryP NU\XS5dwW0GQR1XS
NCI-H2126 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTdwN{O2NlUh|ryP NYX2b5ZUW0GQR1XS
MEL-HO MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrITJRKSzVyPUeuO|cxPTRizszN MYLTRW5ITVJ?
CAPAN-1 M{DnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTdwN{ezOVch|ryP MWjTRW5ITVJ?
SW756 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfLcWp7UUN3ME23Mlc5OzN|IN88US=> MVTTRW5ITVJ?
SKG-IIIa M3:4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXJTWM2OD15LkixPFkzKM7:TR?= MXjTRW5ITVJ?
HCE-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTQUnRKSzVyPUeuPFc4QDNizszN Mn7IV2FPT0WU
Ca-Ski M3:3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S2T2lEPTB;Nz65PVM5OyEQvF2= MWnTRW5ITVJ?
COLO-684 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHKTWM2OD16LkCxPFE5KM7:TR?= MkL2V2FPT0WU
KYSE-70 NYrIflR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[5eXVDUUN3ME24MlA4PzJ7IN88US=> NWTYfW56W0GQR1XS
TI-73 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPxPJpPUUN3ME24MlI2QDVzIN88US=> NIDTdlBUSU6JRWK=
BT-20 M1XB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\OfGlEPTB;OD6yOlA2OiEQvF2= NFrrNXZUSU6JRWK=
MHH-ES-1 NFO2[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXXe2JtUUN3ME24MlUyQDN2IN88US=> NEfacIZUSU6JRWK=
TE-12 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRThwNUm5N|Eh|ryP NVvuNFd3W0GQR1XS
YH-13 M3q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\MbGlEPTB;OD62NVAxQCEQvF2= MnjmV2FPT0WU
SF126 M1Pn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRThwOEO4OlUh|ryP M2nrSnNCVkeHUh?=
J82 M4nG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDORppiUUN3ME24MlkxODN6IN88US=> MkPFV2FPT0WU
RCC10RGB M{jNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRThwOUm1OlEh|ryP NGDTd|JUSU6JRWK=
SK-UT-1 NUfNPZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\x[GlEPTB;OT6wOFk1PSEQvF2= NW\qbI84W0GQR1XS
LB2241-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O0eWlEPTB;OT6xPVE{PyEQvF2= MoPnV2FPT0WU
LB996-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jWOmlEPTB;OT6xPVg6KM7:TR?= MnewV2FPT0WU
EPLC-272H MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXsNYpKSzVyPUmuN|c3PTdizszN NHfTfmFUSU6JRWK=
CTV-1 NXG4WlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\xTWM2OD17LkW2OVMzKM7:TR?= NHHtbZZUSU6JRWK=
HSC-2 NXTVOVRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILL[2hKSzVyPUmuOVc2PSEQvF2= M2P3b3NCVkeHUh?=
SK-MEL-28 NFPMPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX74cpc6UUN3ME25MlYyQDl|IN88US=> M1n2fnNCVkeHUh?=
MMAC-SF NFLFXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTlwNki3OUDPxE1? MYrTRW5ITVJ?
CP50-MEL-B MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTlwN{W3PFIh|ryP M3vtfnNCVkeHUh?=
HT-1080 M363TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW0Um5KSzVyPUmuO|c4OzlizszN NVH5[XY4W0GQR1XS
HEC-1 M1W0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFyLkOzOVIh|ryP MnuxV2FPT0WU
AGS M4XESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPXTWM2OD1zMD6zO|Qh|ryP M1PrTHNCVkeHUh?=
GAMG NVfrfHVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XRTGlEPTB;MUCuOVE3OiEQvF2= NInx[XVUSU6JRWK=
SW48 NXn6cJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S3cmlEPTB;MUCuOVE5QSEQvF2= M{jZOHNCVkeHUh?=
U031 M3rUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljSTWM2OD1zMD61PVA5KM7:TR?= NX6xSmFqW0GQR1XS
OVCAR-5 NHryeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfje3VKSzVyPUGwMlY1OjlizszN M163e3NCVkeHUh?=
SF295 NGf0R3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmryTWM2OD1zMD62O|A1KM7:TR?= MVrTRW5ITVJ?
BHT-101 NW\3[FR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjHeo9KSzVyPUGwMlcyPzdizszN NGT0VJBUSU6JRWK=
VMRC-RCZ NU\LenFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37yVWlEPTB;MUGuN|IxOSEQvF2= NVK2VWM6W0GQR1XS
ACHN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;TUGNxUUN3ME2xNU41OjFzIN88US=> MWLTRW5ITVJ?
NCI-H526 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFzLkWwOFMh|ryP M4\CXHNCVkeHUh?=
MN-60 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLyTWM2OD1zMT61N|kh|ryP MkLoV2FPT0WU
NCI-H2291 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\BTmlEPTB;MUGuOVQ3PiEQvF2= MVTTRW5ITVJ?
SCC-25 NELJT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzwPYhoUUN3ME2xNU44PTV4IN88US=> Ml[wV2FPT0WU
SK-MEL-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFzLke2N|ch|ryP NXTmTpFnW0GQR1XS
SN12C MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf1ZXZKSzVyPUGxMlk{PTVizszN NF:1S|VUSU6JRWK=
NCI-H69 NWXEWG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;hTGlEPTB;MUKuOFI{PCEQvF2= NXnweoRFW0GQR1XS
ME-180 NWroSm5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZTWM2OD1zMj63NFU1KM7:TR?= Mn3ZV2FPT0WU
MC-IXC M1jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vYZmlEPTB;MUKuO|UyQCEQvF2= NXjLRldqW0GQR1XS
NCI-H2347 NX7tTlIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF{Lke2NVQh|ryP NUHKNlBOW0GQR1XS
M059J MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF{Lke3Nlch|ryP NXHNUlRkW0GQR1XS
A2058 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfvbmtFUUN3ME2xNk45PjhzIN88US=> M3joeHNCVkeHUh?=
VA-ES-BJ NWG0VHBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF{Lki3PFUh|ryP NGfSWYxUSU6JRWK=
Ca9-22 NWXUeHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF{Lkm0OVEh|ryP M4XIXXNCVkeHUh?=
KNS-42 NFPGTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF{Lkm5PFQh|ryP MXLTRW5ITVJ?
LoVo NUniZpZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfQeXdbUUN3ME2xN{4zOzF|IN88US=> MlvMV2FPT0WU
AM-38 NWO1fIV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjGTHdsUUN3ME2xN{4zPTZ4IN88US=> MoHuV2FPT0WU
NB5 NHvob|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXyO|JkUUN3ME2xN{4{PzV{IN88US=> Ml;0V2FPT0WU
L-363 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC1TWM2OD1zMz60NFM{KM7:TR?= MX;TRW5ITVJ?
SK-MEL-30 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu1OGFKSzVyPUG0MlA3PDVizszN NXTIT3lRW0GQR1XS
NCI-H1563 NEfKN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LucmlEPTB;MUSuOlA{QSEQvF2= MYrTRW5ITVJ?
NCI-H2228 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF2Lk[wO|ch|ryP M33UcHNCVkeHUh?=
MFM-223 NFj5V41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTaTWM2OD1zNT6xPFE{KM7:TR?= M4D0VXNCVkeHUh?=
LB831-BLC NYfTepl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO2dGJXUUN3ME2xOU4zPzZ5IN88US=> MoXzV2FPT0WU
SW872 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DYemlEPTB;MUWuN|A5PiEQvF2= Ml3HV2FPT0WU
NCI-H522 M2rjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF3LkOzNFYh|ryP NV;jWXNrW0GQR1XS
EW-1 NIPLWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PMWmlEPTB;MUWuOVQ3OiEQvF2= M4\ISXNCVkeHUh?=
HN MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2naOWlEPTB;MUWuOVk1OiEQvF2= MWTTRW5ITVJ?
SW837 NUfUWWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF3Lke4OFch|ryP NILPSXdUSU6JRWK=
SCC-9 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXsTIZKSzVyPUG1MlgyOTRizszN NWrKUmRsW0GQR1XS
MKN7 NXXNe|BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXRVHJMUUN3ME2xOU46PzN{IN88US=> M4nYO3NCVkeHUh?=
KYSE-410 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvJRm5uUUN3ME2xOk42QTFizszN MmXYV2FPT0WU
SK-N-DZ NE[5XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP4OnVKSzVyPUG2MlYyOTZizszN M{jvcnNCVkeHUh?=
COR-L105 NH;2T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF4Lk[1Nlgh|ryP NXvreIVuW0GQR1XS
LB2518-MEL NWe5RlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3LTWM2OD1zNj64N|g6KM7:TR?= M{Kwd3NCVkeHUh?=
OVCAR-4 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS1TWM2OD1zNj64PFYzKM7:TR?= MmXHV2FPT0WU
TK10 Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF4Lkm0O|Mh|ryP MY\TRW5ITVJ?
KNS-62 NIP3[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TiZmlEPTB;MU[uPVc4PyEQvF2= MmDOV2FPT0WU
RPMI-8866 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjFfZJKSzVyPUG3MlE4OzJizszN NH7Wc5BUSU6JRWK=
HuP-T4 NXHrXXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonUTWM2OD1zNz6yOFk2KM7:TR?= NFzEPYhUSU6JRWK=
CGTH-W-1 NYPkSZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofnTWM2OD1zNz61NlE6KM7:TR?= NWjMR5ZCW0GQR1XS
T-24 M2XXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF5LkWzOFch|ryP MUDTRW5ITVJ?
HT-3 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzlcZJNUUN3ME2xO{42QTF2IN88US=> NVXJZ|dYW0GQR1XS
KS-1 NH\ldJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPOW3ltUUN3ME2xO{43PzNizszN MWrTRW5ITVJ?
NCI-H1792 M{T0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17UcWlEPTB;MUeuO|k5KM7:TR?= MVzTRW5ITVJ?
ABC-1 Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHHVGpuUUN3ME2xO{45OTRzIN88US=> NXzHeoxSW0GQR1XS
BPH-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrETWM2OD1zOD6xOlg2KM7:TR?= M1;re3NCVkeHUh?=
A431 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M362emlEPTB;MUiuOFEzPyEQvF2= MU\TRW5ITVJ?
T98G MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PH[GlEPTB;MUiuOVE2PyEQvF2= MVfTRW5ITVJ?
BHY NHrmTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF6Lki2PUDPxE1? M4raXHNCVkeHUh?=
Capan-2 NITZU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\JZY5KSzVyPUG4MlkxPzhizszN NFL3ZVFUSU6JRWK=
MDA-MB-175-VII NWH1RZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrtfpNSUUN3ME2xPE46OjB7IN88US=> MmO3V2FPT0WU
CAL-27 M1nBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nHeGlEPTB;MUmuNFQ5PyEQvF2= M2\ESnNCVkeHUh?=
AsPC-1 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF7Lki2OVch|ryP MkDZV2FPT0WU
KU812 NEn0b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTTdW5KSzVyPUG5Mlk2PzNizszN M3Ltc3NCVkeHUh?=
NCI-H441 NH;VZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP4TW5KSzVyPUKwMlAxOSEQvF2= Ml\hV2FPT0WU
Mewo NHjIUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPobWg6UUN3ME2yNE4yOjh6IN88US=> NVu4TlVYW0GQR1XS
SK-MEL-24 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJyLkG0O|ch|ryP MlvxV2FPT0WU
NCI-H727 NYrwN29NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjEN5FiUUN3ME2yNE4zPzB2IN88US=> NVO2T2Q2W0GQR1XS
EKVX MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJyLk[wOkDPxE1? NFvweXVUSU6JRWK=
RT-112 M1vUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\lT2lEPTB;MkCuOlEzOiEQvF2= MX3TRW5ITVJ?
CAMA-1 M361O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYexOYg3UUN3ME2yNE46QDB|IN88US=> MnX0V2FPT0WU
SW900 M4rJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\tc|c1UUN3ME2yNU4xOTR7IN88US=> MVnTRW5ITVJ?
NCI-H23 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu2UFA4UUN3ME2yNU4yOjd5IN88US=> M4L3VHNCVkeHUh?=
SK-PN-DW MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPHdmpUUUN3ME2yNU4yPjR7IN88US=> NVvTRld3W0GQR1XS
BB30-HNC MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ZTWM2OD1{MT6yO|Q2KM7:TR?= M2TkTXNCVkeHUh?=
VM-CUB-1 NWLhXldUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\IOHUxUUN3ME2yNU4{PTN4IN88US=> NIjseXVUSU6JRWK=
IST-MEL1 NHXGZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOze5JHUUN3ME2yNU4{Pjl{IN88US=> MonhV2FPT0WU
CTB-1 NWSx[3J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HnemlEPTB;MkGuOFc2PSEQvF2= M2nVWHNCVkeHUh?=
LCLC-103H NUfBWZd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zPOWlEPTB;MkKuNVU5OiEQvF2= MXfTRW5ITVJ?
PANC-03-27 NHO4T2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ{LkWxOlkh|ryP M1jsNXNCVkeHUh?=
HTC-C3 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfUOoZKSzVyPUKyMlU2PTVizszN M4[2XHNCVkeHUh?=
TE-8 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TPUmlEPTB;MkOuNlU3PSEQvF2= NUm4RYJXW0GQR1XS
NCI-H292 NHLQcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFeyOGhKSzVyPUK1MlM2OzZizszN NF3SSnZUSU6JRWK=
COLO-680N NVnvXFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ3Lk[zNlkh|ryP NVzPZpJoW0GQR1XS
KYSE-520 NFX4TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPTWM2OD1{NT62OFQh|ryP NEnjbVNUSU6JRWK=
NB10 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXHTWM2OD1{Nj6zNVE4KM7:TR?= NWXoN3ROW0GQR1XS
NCI-H661 NY\FV5J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ4LkS3NVMh|ryP Ml7wV2FPT0WU
GMS-10 M3jHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHWVGtlUUN3ME2yOk45PjN6IN88US=> MYXTRW5ITVJ?
NCI-H2122 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnpZXVXUUN3ME2yOk46QTl6IN88US=> MYfTRW5ITVJ?
OVCAR-8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX4SIpxUUN3ME2yO{4xPjN6IN88US=> MUTTRW5ITVJ?
DJM-1 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm0TJpKSzVyPUK3MlE1PTRizszN Mm[0V2FPT0WU
UACC-893 M1zQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr2R3pKSzVyPUK3Mlk5PzhizszN M3f5ZXNCVkeHUh?=
C8166 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fpcmlEPTB;MkiuOlk{QCEQvF2= MnrsV2FPT0WU
NCI-H1693 NXO4fW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\6SGlEPTB;MkiuOlk4PSEQvF2= MUfTRW5ITVJ?
TYK-nu MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS5OnBKSzVyPUOwMlA{PDVizszN NFzSUJFUSU6JRWK=
SW1710 NYHJZndsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPVTWM2OD1|MD6xNlYh|ryP MorsV2FPT0WU
A375 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNyLkOyOFMh|ryP MoPUV2FPT0WU
HMV-II MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXsZ2NKSzVyPUOxMlM2QTJizszN MXTTRW5ITVJ?
NCI-H2087 M3Psc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNzLk[zOVIh|ryP MmSyV2FPT0WU
CAL-54 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnXOJhRUUN3ME2zNU44OjRzIN88US=> MVnTRW5ITVJ?
HCC70 NXe3fZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILUbIlKSzVyPUOyMlE{QDdizszN NHnTcmtUSU6JRWK=
ES1 NWG1UnlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M375ZmlEPTB;M{KuN|A3OiEQvF2= MUnTRW5ITVJ?
NCI-H1355 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPr[YRtUUN3ME2zN{4zODRizszN Ml7EV2FPT0WU
CFPAC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPy[ZFKSzVyPUOzMlI{OzJizszN Mli0V2FPT0WU
MKN28 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN|LkO4NFkh|ryP MYjTRW5ITVJ?
HDLM-2 NWDiNlVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXtWnZSUUN3ME2zN{43QTNzIN88US=> M2raV3NCVkeHUh?=
PANC-10-05 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrtS2hKSzVyPUO0MlExOTRizszN M1[0T3NCVkeHUh?=
SAS M{n3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHEZo1kUUN3ME2zOE41PTZ3IN88US=> M{HIOHNCVkeHUh?=
HCC1395 NFXWVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\XOGVKSzVyPUO0MlcyQDZizszN M{LaT3NCVkeHUh?=
8305C MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:5NmNKSzVyPUO1Mlg1OTVizszN MWTTRW5ITVJ?
KM12 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\nWllsUUN3ME2zOk44PTR5IN88US=> MWjTRW5ITVJ?
SW1116 M4\h[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37BNGlEPTB;M{euOVk6OiEQvF2= NIfaU2pUSU6JRWK=
SK-MEL-1 M4rvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfI[oN{UUN3ME2zPE4{Ozh7IN88US=> M2nmTXNCVkeHUh?=
HCC2218 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\jb3VKSzVyPUO4MlY2OTlizszN MnvSV2FPT0WU
T84 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;4VWJ[UUN3ME2zPE44PDB7IN88US=> M{fzbHNCVkeHUh?=
ETK-1 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG4TWM2OD1|OT6wNlIh|ryP NF\oNnNUSU6JRWK=
COLO-800 NUf4S3JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHpSFJmUUN3ME2zPU4{QDZ6IN88US=> M2mwOnNCVkeHUh?=
CAL-12T MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN7LkWyPFEh|ryP NFjtVIpUSU6JRWK=
ACN NGrZTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq4TGh{UUN3ME20NE41QTFzIN88US=> MX;TRW5ITVJ?
SJSA-1 NXy4NXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOw[GRjUUN3ME20NU4yPTl4IN88US=> NUjTTG1EW0GQR1XS
PSN1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXBTWM2OD12MT6xO|Q6KM7:TR?= Mn\nV2FPT0WU
D-566MG M2\jSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HmcWlEPTB;NEGuNlA5PiEQvF2= MXrTRW5ITVJ?
EGI-1 M33hOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTR{LkSyPEDPxE1? NVHQWHgxW0GQR1XS
A204 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTR{Lk[zPFgh|ryP NEXDXnRUSU6JRWK=
Saos-2 NXzPdHVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrybo9UUUN3ME20Nk45OzZ7IN88US=> M2fUe3NCVkeHUh?=
SNU-C2B NUDHXnVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV2xcGc4UUN3ME20N{43QDd6IN88US=> MUjTRW5ITVJ?
HLE NWfL[|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\3NmlEPTB;NESuNFg2PiEQvF2= NHW1clFUSU6JRWK=
SW1463 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\JV3RTUUN3ME20OE46QTdzIN88US=> NXKweFI{W0GQR1XS
DSH1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3wTWM2OD12NT6wNFM{KM7:TR?= MUfTRW5ITVJ?
MCF7 NF7n[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnrTo5KSzVyPUS1MlUxPTFizszN MYnTRW5ITVJ?
K5 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTR3Lkm0NFUh|ryP NWrve41iW0GQR1XS
NCI-H358 M4WxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR5LkKxOUDPxE1? MWTTRW5ITVJ?
NCI-H2030 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDnUnlKSzVyPUS3MlI{PzRizszN NVqyT5hIW0GQR1XS
SW948 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDxTWM2OD12Nz60OlQh|ryP Ml;FV2FPT0WU
BALL-1 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzYb|NKSzVyPUS3MlYyPjhizszN NIDIV4pUSU6JRWK=
TE-9 NWHVdo5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHy[IFKSzVyPUS3Mlk2QDFizszN M2m4UHNCVkeHUh?=
SK-N-FI MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jySGlEPTB;NEiuNFM2QCEQvF2= MVvTRW5ITVJ?
KALS-1 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W2WmlEPTB;NEiuNVI5QSEQvF2= MnjpV2FPT0WU
HO-1-N-1 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR6Lke0OFUh|ryP NYTxRXNVW0GQR1XS
NCI-H2452 NIjLNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPyeoFbUUN3ME20PU4yOTV{IN88US=> M37xc3NCVkeHUh?=
OC-314 NUDjVmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn3OmRKSzVyPUS5MlY5OzRizszN MUDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1
NCT02079740 Recruiting Advanced Malignant Solid Neoplasm|KRAS Gene Mutation|Metastatic Malignant Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Malignant Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT02520778 Recruiting EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.G719X|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.L861Q|EGFR NP_005219.2:p.T790M|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 28 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID